Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical trial of cetuximab injection biosimilar HLX05-N.
The drug is being tested in patients with metastatic colorectal cancer in Mainland China, according to a Wednesday Hong Kong bourse filing.